glp-1 trump deal The $50 Deal: Facts, Feelings & Speculation? GLP-1 Drug Price Cut: Trump

Analysts see US focused alcohol companies facing the most exposure from increased obesity medicine usage and expect a roughly 2% drop in consumption by 2035. As for GLP-1 drug users, survey data from the Brightfield Group suggests that a substantial portion are city dwellers with higher incomes that are actively engaged in exercise and diet management, while a recent survey of 2,000 US consumers from direct-to-consumer company Daily Harvest found that GLP-1 drugs were more appealing to those with self-described very healthy diets

It is important to note that permitted application sites vary significantly between different transdermal medications

People with very high-dose needs of insulin are typically very insulin resistant

About 3.6 million Medicare beneficiaries potentially qualify

By suppressing glucagon, GLP-1 further contributes to better glucose control

Spending on Ozempic increased significantly between 2021 and 2022, rising from 10th to 6th place, respectively, in the top-selling Part D drugs